澳大利亚生物技术公司Adalta Ltd与合作伙伴Oribiotech、Cell Therapies共同签署了一份具有战略意义的谅解备忘录。该协议旨在将创新的Iro技术平台推广至澳大利亚及亚太地区。
这一合作标志着三方在细胞治疗领域的深度协同。通过资源整合与技术共享，合作伙伴计划加速Iro平台在亚太市场的商业化进程，为当地医疗健康产业注入新的技术活力。
此次布局不仅展现了Adalta Ltd在全球生物技术领域的战略眼光，也预示着亚太地区将成为细胞治疗技术发展的重要增长极。合作各方将共同探索该技术在不同医疗场景中的应用潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.